gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · ENTAHealthcarePharmaceuticals

Enanta Pharmaceuticals, Inc (ENTA)

$10.73+3.47%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$10.73▼ 0.74% in range
Nov 4, 2025Low $10.37 · High $16.85Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Enanta Pharmaceuticals closed at $10.73 on Nov 4, up 3.47%, 36.3% below its 52-week closing high. Volume of 97.5K shares was 0.42× its 20-day average (below normal).

Split-adjusted performance: -11.8% over one month, -29.6% over six months, -0.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $14.36M, down 21.6% from a year earlier, with a net margin of -135.8%.

Short interest was 2.3M shares at the Oct 15 settlement, down 11.3% from the prior report (8.2% of float, 8.6 days to cover).

Market cap$312.5M29.1M shares
Revenue · quarter$14.4M−21.6% YoY
Diluted EPS$-0.67—
P/E · TTM—P/S 4.8×
Net margin-135.8%Gross 100.0%
Dividend yieldNone
52-week range10.37 – 16.85−36.3% from high
Volume97.5K0.42× 20-day avg
Volatility · 60d46.0%Annualised
Short % of float8.2%8.6 days to cover
Net cash$189.5MCash $189.5M
Next earnings—Not scheduled
Split-adjusted performance
1W −7.1%1M −11.8%3M −19.6%6M −29.6%YTD −32.0%1Y −0.8%3Y +21.7%5Y −86.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum46
Revenue growth29
Net margin42
Value (low P/E)—
Size54

Industry medians: 6-month return −25.3%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short2.3M−11.3% vs prior
Days to cover8.6Settled Oct 15
% of float8.2%
Short vol. 10d52.1%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ENTAEnanta Pharmaceuticals$10.73+3.47%−29.6%−21.6%−135.8%—$312.5M
CYPHCypherpunk Technologies$2.90+11.54%+156.6%———$312.5MCompare
BNTCBenitec Biopharma$8.97+6.79%−28.6%———$313.0MCompare
EBSEmergent Biosolutions$6.06−3.12%−33.5%−52.4%−29.7%—$310.5MCompare
CGCCanopy Growth$0.7520+6.41%−34.6%+7.8%−18.0%—$318.1MCompare
SPRYARS Pharmaceuticals$3.08+0.82%−66.9%+114.2%−185.2%—$305.8MCompare
PRLDPrelude Therapeutics Incorporated$4.08+7.94%−15.7%—−244.1%—$325.6MCompare
ARCTArcturus Therapeutics Holdings$10.54+10.48%+15.4%−89.5%−803.8%—$299.6MCompare
TTRXTurn Therapeutics$9.84+3.47%+159.3%———$298.8MCompare

News about Enanta Pharmaceuticals

All news →

No recent articles focused on Enanta Pharmaceuticals.

Quick answers

What does Enanta Pharmaceuticals do?
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology.
What is ENTA's market cap?
$312.52M, based on the Nov 4 close of $10.73.
Does Enanta Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ENTA is sold short?
2.3M shares, 8.2% of float, as of Oct 15, 2026.
What sector is ENTA in?
Healthcare, in the Pharmaceuticals industry.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

HQ: Watertown, MA120 employeesListed Mar 21, 2013enanta.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology